Eli Lilly to give some patients early access to next-gen obesity drug

• Eligible patients must be 18+, have refractory obesity despite maximum approved therapy, at least two serious obesity-related complications, and be unable to join clinical trials
• Retatrutide targets three hormones (GLP-1, GIP, and glucagon) compared to Lilly's current Zepbound drug which targets only two (GLP-1 and GIP)
• An 80-week trial showed 22.6% average weight loss at the highest weekly dose among adults with severe obesity and established heart disease

Summary: Eli Lilly Grants Early Access to Experimental Obesity Drug Retatrutide

Eli Lilly announced Monday it will provide limited early access to its next-generation obesity drug, retatrutide, before FDA approval through an expanded access program. The initiative aligns with FDA guidance and targets patients meeting strict medical criteria who cannot participate in clinical trials.

Eligibility Requirements:

Patients must be 18 or older, have refractory obesity despite tolerating maximum approved obesity therapy doses, present at least two serious or life-threatening obesity-related complications under treatment, and be unable to join ongoing retatrutide clinical trials.

Drug Profile and Performance:

Retatrutide represents an advancement over Lilly's current obesity drug Zepbound. While Zepbound targets two metabolic hormones (GLP-1 and GIP), retatrutide targets three: GLP-1, GIP, and glucagon. In an 80-week trial of adults with severe obesity and established heart disease, the highest weekly dose achieved average weight loss of 22.6%.

Timeline and Market Implications:

Lilly plans to file for FDA approval in Q1 next year. The early access program demonstrates the company's aggressive strategy in the competitive obesity drug market, potentially building patient experience and clinical data ahead of formal approval. This move also addresses counterfeit drug concerns by providing authentic medication to qualifying patients.

The announcement comes as pharmaceutical companies intensify competition in the lucrative obesity treatment sector, with Lilly positioning retatrutide as a superior alternative to existing therapies through its triple-hormone mechanism and impressive weight loss results.